NASDAQ:KNSA

Kiniksa Pharmaceuticals News Headlines

$16.54
+0.03 (+0.18 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.94
Now: $16.54
$16.97
50-Day Range
$15.47
MA: $19.23
$23.91
52-Week Range
$14.51
Now: $16.54
$28.67
Volume345,535 shs
Average Volume506,482 shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.03

Headlines

Kiniksa Pharmaceuticals (NASDAQ KNSA) News Headlines Today

SourceHeadline
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sees Unusually-High Trading VolumeKiniksa Pharmaceuticals (NASDAQ:KNSA) Sees Unusually-High Trading Volume
americanbankingnews.com - April 20 at 1:40 PM
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Down 4.8%Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Down 4.8%
americanbankingnews.com - April 17 at 9:08 AM
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 PatientsKiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
finance.yahoo.com - April 12 at 11:33 AM
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Expected to Post Earnings of -$0.74 Per ShareKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Expected to Post Earnings of -$0.74 Per Share
americanbankingnews.com - April 7 at 12:08 AM
Kiniksa Announces Commercial Availability of ARCALYST (R) (rilonacept) for Recurrent PericarditisKiniksa Announces Commercial Availability of ARCALYST (R) (rilonacept) for Recurrent Pericarditis
marketwatch.com - April 1 at 1:49 PM
Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent PericarditisKiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
finance.yahoo.com - April 1 at 8:49 AM
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Up 5.8%Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Up 5.8%
americanbankingnews.com - March 29 at 2:37 PM
Kiniksa Announces FDA Approval of ARCALYST (R) (rilonacept) for Recurrent PericarditisKiniksa Announces FDA Approval of ARCALYST (R) (rilonacept) for Recurrent Pericarditis
marketwatch.com - March 19 at 9:59 AM
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent PericarditisKiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
finance.yahoo.com - March 19 at 9:59 AM
Kiniksa Launches Patient Registry (RESONANCE) for Recurrent PericarditisKiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
finance.yahoo.com - March 2 at 9:42 AM
Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline ActivityKiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
finance.yahoo.com - February 23 at 9:57 AM
Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and HyperinflammationKiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
finance.yahoo.com - December 22 at 10:16 AM
Notable Friday Option Activity: KNSA, OKTA, CZRNotable Friday Option Activity: KNSA, OKTA, CZR
nasdaq.com - December 18 at 6:55 PM
Is KNSA A Good Stock To Buy Now?Is KNSA A Good Stock To Buy Now?
finance.yahoo.com - December 18 at 1:55 PM
Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo NodularisKiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis
finance.yahoo.com - December 15 at 1:00 PM
Kiniksa Pharmas KPL-404 shows encouraging action in early-stage studyKiniksa Pharma's KPL-404 shows encouraging action in early-stage study
seekingalpha.com - November 30 at 3:56 PM
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
finance.yahoo.com - November 30 at 9:27 AM
Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent PericarditisKiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
finance.yahoo.com - November 23 at 8:23 AM
Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020
finance.yahoo.com - November 17 at 8:42 AM
Kiniksas vixarelimab nabs accelerated review in U.S. for a skin disorderKiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
seekingalpha.com - November 16 at 6:37 PM
Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo NodularisKiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
finance.yahoo.com - November 16 at 8:35 AM
Heres Why Were Not Too Worried About Kiniksa Pharmaceuticals (NASDAQ:KNSA) Cash Burn SituationHere's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
finance.yahoo.com - November 10 at 1:05 PM
Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis DataKiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
finance.yahoo.com - November 9 at 6:36 PM
Kiniksa Pharmaceuticals Ltd.Kiniksa Pharmaceuticals Ltd.
barrons.com - November 2 at 1:58 PM
Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual CongressKiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis to be Presented at European Academy of Dermatology and Venereology Virtual Congress
finance.yahoo.com - October 29 at 1:03 PM
Kiniksa reports additional mavrilimumab dataKiniksa reports additional mavrilimumab data
seekingalpha.com - October 26 at 1:50 PM
Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020
finance.yahoo.com - October 26 at 8:49 AM
Stock Alert: Kiniksa Pharma Jumps 15% On Positive Data From Mavrilimumab StudyStock Alert: Kiniksa Pharma Jumps 15% On Positive Data From Mavrilimumab Study
nasdaq.com - October 6 at 2:35 PM
Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell ArteritisKiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
markets.businessinsider.com - October 6 at 9:35 AM
Positive mavrilimumab data lifts Kiniksa, up 14%Positive mavrilimumab data lifts Kiniksa, up 14%
seekingalpha.com - October 6 at 9:35 AM
Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29thKiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th
finance.yahoo.com - September 24 at 5:18 PM
Kiniksa Announces Upcoming Rilonacept Analyst DayKiniksa Announces Upcoming Rilonacept Analyst Day
finance.yahoo.com - September 21 at 12:27 PM
Kiniksas mavrilimumab an orphan drugKiniksa's mavrilimumab an orphan drug
seekingalpha.com - September 15 at 12:43 PM
Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell ArteritisKiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
finance.yahoo.com - September 15 at 12:43 PM
Kiniksa Pharmaceuticals, Ltd. - Class AKiniksa Pharmaceuticals, Ltd. - Class A
benzinga.com - August 18 at 1:41 PM
Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare ConferenceKiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 4 at 9:41 AM
Kiniksa Pharmaceuticals EPS misses by $0.10Kiniksa Pharmaceuticals EPS misses by $0.10
seekingalpha.com - July 30 at 8:26 AM
Do Insiders Own Lots Of Shares In Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?Do Insiders Own Lots Of Shares In Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
finance.yahoo.com - July 28 at 6:25 PM
Kiniksa Pharma prices stock offering at $21Kiniksa Pharma prices stock offering at $21
seekingalpha.com - July 22 at 6:42 AM
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public OfferingKiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering
finance.yahoo.com - July 21 at 10:49 PM
14 Stocks Moving In Mondays After-Hours Session14 Stocks Moving In Monday's After-Hours Session
www.msn.com - July 20 at 7:59 PM
Kiniksa Pharma to raise $100M in equityKiniksa Pharma to raise $100M in equity
seekingalpha.com - July 20 at 7:59 PM
Kiniksa launches $100M stock offeringKiniksa launches $100M stock offering
seekingalpha.com - July 20 at 7:59 PM
Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of PericarditisKiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
finance.yahoo.com - July 16 at 9:16 AM
Hedge Funds Are Betting On Kiniksa Pharmaceuticals, Ltd. (KNSA)Hedge Funds Are Betting On Kiniksa Pharmaceuticals, Ltd. (KNSA)
finance.yahoo.com - July 6 at 8:16 AM
Kiniksas Heart Drug, And Other News: The Good, Bad, And Ugly Of BiopharmaKiniksa's Heart Drug, And Other News: The Good, Bad, And Ugly Of Biopharma
seekingalpha.com - June 30 at 3:48 PM
Company News for Jun 30, 2020Company News for Jun 30, 2020
finance.yahoo.com - June 30 at 10:47 AM
Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia GroupZacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
finance.yahoo.com - June 30 at 10:47 AM
FDA Snubs HRTX Again, ICPT Disappoints, KNSA Hits Right Notes, Is The Writing On The Wall For VRCA?FDA Snubs HRTX Again, ICPT Disappoints, KNSA Hits Right Notes, Is The Writing On The Wall For VRCA?
www.nasdaq.com - June 30 at 5:47 AM
Why Kiniksas Stock Is Trading Higher TodayWhy Kiniksa's Stock Is Trading Higher Today
www.benzinga.com - June 29 at 12:40 PM
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.